A new medical research may have found the therapy to overcome skin cancer. According to a study published yesterday in the Journal of Clinical Oncology, a drug based on the ‘herpes simplex’, called T-Vec, has been used successfully to treat aggressive melanoma. The study was conducted by the Institute of Cancer Research in London, which showed that the herpes virus is able to activate an immune reaction after having infected the cancer cells, and to finally destroy them.
It is the first research based on this new approach and the results have been really positive, so much positive that the researchers have decided to publish the data, wishing to receive the approval of the US Food and Drug Administration and of the European counterpart to authorize the T-Vec therapy (Talimogene Laherparepvec) produced by Amgen. Using a virus as a medicine constitutes no novelty, but its genetic manipulation opens the way to promising possibilities.
436 patients with aggressive melanoma were treated with T-Vec or with another immunotherapeutic. More than 16% of those treated with the modified Herpes Virus were still in remission after six months.
Translation provided by Maria Rosaria Mastropaolo